BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17918921)

  • 21. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
    Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
    J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.
    Zhou D; Gross JL; Adedoyin AB; Aschmies SB; Brennan J; Bowlby M; Di L; Kubek K; Platt BJ; Wang Z; Zhang G; Brandon N; Comery TA; Robichaud AJ
    J Med Chem; 2012 Mar; 55(5):2452-68. PubMed ID: 22313242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.
    Morini G; Comini M; Rivara M; Rivara S; Bordi F; Plazzi PV; Flammini L; Saccani F; Bertoni S; Ballabeni V; Barocelli E; Mor M
    Bioorg Med Chem; 2008 Dec; 16(23):9911-24. PubMed ID: 18976927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent and selective histamine H3 receptor inverse agonists based on the 3,4-dihydro-2H-pyrazino[1,2-a]indol-1-one scaffold.
    Richter HG; Freichel C; Huwyler J; Nakagawa T; Nettekoven M; Plancher JM; Raab S; Roche O; Schuler F; Taylor S; Ullmer C; Wiegand R
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5713-7. PubMed ID: 20801030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyclobutanecarboxamide (PF-03654764).
    Wager TT; Pettersen BA; Schmidt AW; Spracklin DK; Mente S; Butler TW; Howard H; Lettiere DJ; Rubitski DM; Wong DF; Nedza FM; Nelson FR; Rollema H; Raggon JW; Aubrecht J; Freeman JK; Marcek JM; Cianfrogna J; Cook KW; James LC; Chatman LA; Iredale PA; Banker MJ; Homiski ML; Munzner JB; Chandrasekaran RY
    J Med Chem; 2011 Nov; 54(21):7602-20. PubMed ID: 21928839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of a new class of non-imidazole oxazoline-based histamine H(3) receptor (H(3)R) inverse agonists.
    Célanire S; Wijtmans M; Christophe B; Collart P; de Esch I; Dassesse D; Delaunoy C; Denonne F; Durieu V; Gelens E; Gillard M; Lallemand B; Lamberty Y; Lebon F; Nicolas JM; Quéré L; Snip E; Vanbellinghen A; Van Houtvin N; Verbois V; Timmerman H; Talaga P; Leurs R; Provins L
    ChemMedChem; 2009 Jul; 4(7):1063-8. PubMed ID: 19405064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of spirofused piperazine and diazepane amides as selective histamine-3 antagonists with in vivo efficacy in a mouse model of cognition.
    Brown DG; Bernstein PR; Griffin A; Wesolowski S; Labrecque D; Tremblay MC; Sylvester M; Mauger R; Edwards PD; Throner SR; Folmer JJ; Cacciola J; Scott C; Lazor LA; Pourashraf M; Santhakumar V; Potts WM; Sydserff S; Giguère P; Lévesque C; Dasser M; Groblewski T
    J Med Chem; 2014 Feb; 57(3):733-58. PubMed ID: 24410637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An 80-amino acid deletion in the third intracellular loop of a naturally occurring human histamine H3 isoform confers pharmacological differences and constitutive activity.
    Bongers G; Krueger KM; Miller TR; Baranowski JL; Estvander BR; Witte DG; Strakhova MI; van Meer P; Bakker RA; Cowart MD; Hancock AA; Esbenshade TA; Leurs R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):888-98. PubMed ID: 17855474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.
    Nagase T; Mizutani T; Ishikawa S; Sekino E; Sasaki T; Fujimura T; Ito S; Mitobe Y; Miyamoto Y; Yoshimoto R; Tanaka T; Ishihara A; Takenaga N; Tokita S; Fukami T; Sato N
    J Med Chem; 2008 Aug; 51(15):4780-9. PubMed ID: 18598020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Search for histamine H(3) receptor ligands with combined inhibitory potency at histamine N-methyltransferase: omega-piperidinoalkanamine derivatives.
    Grassmann S; Apelt J; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Arch Pharm (Weinheim); 2004 Oct; 337(10):533-45. PubMed ID: 15476285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ergoline-derived inverse agonists of the human h3 receptor for the treatment of narcolepsy.
    Auberson YP; Troxler T; Zhang X; Yang CR; Fendt M; Feuerbach D; Liu YC; Lagu B; Lerchner A; Perrone M; Lei L; Zhang C; Wang C; Wang TL; Bock MG
    ChemMedChem; 2014 Aug; 9(8):1683-96. PubMed ID: 24850792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenyl-oxazoles, a new family of inverse agonists at the H(3) histamine receptor.
    Denonne F; Atienzar F; Célanire S; Christophe B; Delannois F; Delaunoy C; Delporte ML; Durieu V; Gillard M; Lallemand B; Lamberty Y; Lorent G; Vanbellinghen A; Van Houtvin N; Verbois V; Provins L
    ChemMedChem; 2010 Feb; 5(2):206-12. PubMed ID: 20043314
    [No Abstract]   [Full Text] [Related]  

  • 34. A new family of H3 receptor antagonists based on the natural product Conessine.
    Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Sengupta D; Duffield JJ; Semple G; Webb RR; Sage C; Ren A; Pereira G; Knudsen J; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Whelan K; Grottick AJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1490-4. PubMed ID: 18194865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists.
    Mor M; Bordi F; Silva C; Rivara S; Zuliani V; Vacondio F; Rivara M; Barocelli E; Bertoni S; Ballabeni V; Magnanini F; Impicciatore M; Plazzi PV
    Bioorg Med Chem; 2004 Feb; 12(4):663-74. PubMed ID: 14759727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
    Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
    J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).
    Gao Z; Hurst WJ; Guillot E; Czechtizky W; Lukasczyk U; Nagorny R; Pruniaux MP; Schwink L; Sanchez JA; Stengelin S; Tang L; Winkler I; Hendrix JA; George PG
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3421-6. PubMed ID: 23591112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
    von Coburg Y; Kottke T; Weizel L; Ligneau X; Stark H
    Bioorg Med Chem Lett; 2009 Jan; 19(2):538-42. PubMed ID: 19091563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists.
    Le S; Gruner JA; Mathiasen JR; Marino MJ; Schaffhauser H
    J Pharmacol Exp Ther; 2008 Jun; 325(3):902-9. PubMed ID: 18305012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
    Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
    J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.